Sugi Predict

Sugi Predict / Compounds / SCHEMBL2768908

SCHEMBL2768908

SCHEMBL2768908

Fc1c(Cl)cccc1N=C=S

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.46
▸ TDP1 Q9NUW8 2/20 0.46
▸ CYP1A2 P05177 2/20 0.46
▸ ABCB11 O95342 1/20 0.46
▸ NR3C1 P04150 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ ADRA2A P08913 1/20 0.46
▸ ADORA3 P0DMS8 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ ALOX15 P16050 1/20 0.46
▸ ADRA2C P18825 1/20 0.46
▸ MAOA P21397 1/20 0.46
▸ DRD1 P21728 1/20 0.46
▸ SLC6A4 P31645 1/20 0.46
▸ HTR2B P41595 1/20 0.46
▸ CCR2 P41597 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ GABRA1 P14867 1/20 0.37
▸ GABRB2 P47870 1/20 0.37
▸ APLNR P35414 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17650697 0.82 ABCB11 (0.34) ALDH1A1TDP1CYP1A2ABCB11NR3C1
SCHEMBL163526 0.80 CYP3A4 (0.50) ALDH1A1TDP1CYP1A2CYP3A4HPGD
SCHEMBL895789 0.79 ALDH1A1 (0.48) ALDH1A1TDP1CYP1A2ABCB11NR3C1
SCHEMBL29668094 0.79 ALDH1A1 (0.48) ALDH1A1TDP1CYP1A2ABCB11NR3C1
SCHEMBL2768046 0.79 ALDH1A1 (0.48) ALDH1A1TDP1CYP1A2ABCB11NR3C1
SCHEMBL29401009 0.79 ALDH1A1 (0.52) ALDH1A1TDP1CYP1A2ABCB11NR3C1
SCHEMBL458499 0.79 ALDH1A1 (0.52) ALDH1A1TDP1CYP1A2ABCB11NR3C1
SCHEMBL17289579 0.78 ALDH1A1 (0.47) ALDH1A1TDP1CYP1A2ABCB11NR3C1
SCHEMBL2770263 0.76 ALDH1A1 (0.46) ALDH1A1TDP1CYP1A2ABCB11NR3C1
SCHEMBL17650413 0.76 ABCB11 (0.33) ALDH1A1TDP1CYP1A2ABCB11NR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118946553-A SARM1 inhibitor compound, pharmaceutical composition comprising the same, and preparation method and use thereof 深圳众格生物科技有限公司 2024-11-12 — — CN disclosed
WO-2023193809-A1 SARM1 INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREFOR AND USES THEREOF 深圳众格生物科技有限公司 2023-10-12 — — WO disclosed
CN-109476696-B Anti-trypanosome and anti-leishmania agents for animals and humans 细胞基因公司 2022-06-10 — — CN disclosed
EP-3464287-B1 ANIMAL AND HUMAN ANTI-MALARIAL AGENTS CELGENE CORP (US) 2022-06-08 — — EP disclosed
US-11344554-B2 Animal and human anti-malarial agents CELGENE CORPORATION (US) 2022-05-31 — — US disclosed
CN-109563095-B Animal and human antimalarial agents 细胞基因公司 2021-10-29 — — CN disclosed
US-20200330469-A1 ANIMAL AND HUMAN ANTI-MALARIAL AGENTS CELGENE CORP (US) 2020-10-22 — — US disclosed
US-10736899-B2 Animal and human anti-malarial agents CELGENE CORPORATION (US) 2020-08-11 — — US disclosed
US-10420771-B2 Animal and human anti-malarial agents CELGENE CORPORATION (US) 2019-09-24 — — US disclosed
US-10420772-B2 Animal and human anti-trypanosomonal and anti-leishmania agents CELGENE CORPORATION (US) 2019-09-24 — — US disclosed
CN-1452483-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORP (US) 2003-10-29 — — CN disclosed
EP-1272175-A2 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2003-01-08 — — EP disclosed
CN-1090623-C 3-aryl-1, 2, 4-triazole derivatives having herbicidal properties BAYER AG (DE) 2002-09-11 — — CN disclosed
CN-1325848-A Herbicidal 3-aryl-1,2,4-triazole derivative BAYER AG (DE) 2001-12-12 — — CN disclosed
WO-2001072960-A2 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2001-10-04 — — WO disclosed
CN-1175249-A 3-aryl-1, 2, 4-triazole derivatives having herbicidal properties BAYER AG (DE) 1998-03-04 — — CN disclosed
US-5393883-A Ribonucleotide reductase inhibitors BURROUGHS WELLCOME CO. (US) 1995-02-28 — — US disclosed
US-5175165-A Acyclovir and a thiocarbonohydrazone ribonucleotide reductase inhibitor for treatment of herpes virus BURROUGHS WELLCOME CO. (US) 1992-12-29 — — US disclosed
EP-0349243-B1 ANTIVIRAL COMBINATIONS AND COMPOUNDS THEREFOR THE WELLCOME FOUNDATION LIMITED (GB) 1992-04-01 — — EP disclosed
EP-0349243-A2 Antiviral combinations and compounds therefor THE WELLCOME FOUNDATION LIMITED (GB) 1990-01-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200330469-A1 ANIMAL AND HUMAN ANTI-MALARIAL AGENTS HPRT1, UMPS, PNP ALDH1A1 1152/4885TDP1 167/4885CYP1A2 395/4885
US-10420771-B2 Animal and human anti-malarial agents HPRT1, UMPS, PNP ALDH1A1 1270/4885TDP1 169/4885CYP1A2 349/4885
US-10736899-B2 Animal and human anti-malarial agents HPRT1, UMPS, PNP ALDH1A1 1152/4885TDP1 167/4885CYP1A2 395/4885
US-11344554-B2 Animal and human anti-malarial agents HPRT1, UMPS, PNP ALDH1A1 1152/4885TDP1 167/4885CYP1A2 395/4885
US-10420772-B2 Animal and human anti-trypanosomonal and anti-leishmania agents TPMT, TYMP, ATIC ALDH1A1 749/4885TDP1 329/4885CYP1A2 1589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.